Cholesteryl Ester Transfer Protein Inhibitors

Learning Objectives

Benefits of Statins on Major Vascular Events

IMPROVE-IT Benefit of Adding the Non-statin Ezetimibe to Statin Therapy

HDL-C and CHD Risk Epidemiologic Observations

Reverse Cholesterol Transport

Reverse Cholesterol Transport and CETP inhibition

Bad Few Years for HDL-C

ILLUMINATE Torcetrapib in Patients at High Risk for Coronary Events

ILLUMINATE Torcetrapib in Patients at High Risk for Coronary Events

dal-OUTCOMES Dalcetrapib in Patients With Recent ACS

dal-OUTCOMES Dalcetrapib Did Not Reduce Risk of Recurrent CV Events

Copenhagen City Heart Study Genetic Inhibition of CETP

Reverse Cholesterol Transport Animal Model

Functionality of Accumulating HDL After Niacin or Anacetrapib Treatment

Novel CETP Inhibitor K-312 Suppresses PCSK9 Expression

Lipid Effects of CETP Inhibitors Summary

Estimation of LDL-C Concentration

Anacetrapib Pharmacokinetics

DEFINE Safety of Anacetrapib in Patients With/at High Risk for CHD

DEFINE Cardiac Events

REVEAL Anacetrapib in Patients With Occlusive Arterial Disease

Evacetrapib Phase 2 Trial Monotherapy or With Statins

Evacetrapib Monotherapy Lipid Changes

Evacetrapib + Statin Therapy HDL-C Changes

Evacetrapib + Statin Therapy LDL-C Changes

Evacetrapib Safety

CETP Inhibitors Will They Work?

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)